Latest Conference Articles

Genetic Testing Cost for Huntington Disease Nonstandard Across Centers of Excellence

Genetic Testing Cost for Huntington Disease Nonstandard Across Centers of Excellence

September 20th 2021, 9:00pm

International Parkinson and Movement Disorders Society Congress

A study from the International Parkinson and Movement Disorder Society Virtual Congress suggest that despite protocol adherence, average costs are moderately high and vary significantly.

Improving Care in Dystonia via Medical Cannabis: Saar Anis, MD

Improving Care in Dystonia via Medical Cannabis: Saar Anis, MD

September 20th 2021, 5:00pm

International Parkinson and Movement Disorders Society Congress

The neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel discussed future use of medical cannabis and concerns for psychiatric adverse effects.

Efficacy of Medical Cannabis for the Treatment of Dystonia: Saar Anis, MD

Efficacy of Medical Cannabis for the Treatment of Dystonia: Saar Anis, MD

September 20th 2021, 1:00pm

International Parkinson and Movement Disorders Society Congress

The neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel outlined the small, retrospective study, shedding light on its findings.

Noncontact Boxing Exercise Assessed for Parkinson Disease Benefit

Noncontact Boxing Exercise Assessed for Parkinson Disease Benefit

September 19th 2021, 7:00pm

International Parkinson and Movement Disorders Society Congress

The FIGHT-PD study is expected to complete and read out interim results before the end of 2021. It aims to assess the exercise program’s safety, tolerability, and efficacy in Parkinson disease.

State of Care for Patients With Parkinson Disease: William Ondo, MD

State of Care for Patients With Parkinson Disease: William Ondo, MD

September 19th 2021, 4:00pm

International Parkinson and Movement Disorders Society Congress

The professor of neurology at Weill Cornell Medical School commented on the available treatments for Parkinson disease, as well as ongoing therapeutic development.

Home Health DBS Management Proves Feasible for Parkinson Disease

Home Health DBS Management Proves Feasible for Parkinson Disease

September 18th 2021, 7:00pm

International Parkinson and Movement Disorders Society Congress

Patients who underwent deep brain stimulation procedures that were managed postoperatively in the home reported significantly fewer clinic visits with similar MDS-UPDRS scores to standard of care.

Medical Cannabis Improves Related Pain, Symptoms of Dystonia

Medical Cannabis Improves Related Pain, Symptoms of Dystonia

September 18th 2021, 4:00pm

International Parkinson and Movement Disorders Society Congress

Investigators noted the psychiatric adverse effects of treatment with medical cannabis, requiring patient monitoring after initiation.

Prasinezumab Shows Potential Effect of Delaying Motor Progression in Parkinson Disease

Prasinezumab Shows Potential Effect of Delaying Motor Progression in Parkinson Disease

September 18th 2021, 2:00pm

International Parkinson and Movement Disorders Society Congress

Despite not meeting the primary end point, those in the early-start group showed reduced change from baseline in MDS-UPDRS-III scores compared with the delayed-start group at both weeks 52 and 104.

COVID-19 Stressors Associated With Poorer Mental Health in Parkinson Disease

COVID-19 Stressors Associated With Poorer Mental Health in Parkinson Disease

September 17th 2021, 9:00pm

International Parkinson and Movement Disorders Society Congress

Data from the PRIME-NL study showed stressors resulting from the pandemic impacted depression, anxiety, and quality of life.

Opicapone Demonstrates Small Benefit for Sleep in Parkinson Disease

Opicapone Demonstrates Small Benefit for Sleep in Parkinson Disease

September 17th 2021, 3:00pm

International Parkinson and Movement Disorders Society Congress

Improvements in mean total amount of time and percentage of participants that were awake suggested limited effect with opicapone (Ogentys; Neurocrine Bio).